Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.71 |
| ▸ | RAF1 | P04049 | 7/20 | 0.71 |
| ▸ | EGFR | P00533 | 6/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2970665 | 0.87 | MAP2K1 (0.73) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL6382750 | 0.83 | MAP2K1 (1.00) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL6182185 | 0.81 | ABL1 (0.69) | MAP2K1RAF1EGFRSRC | |
| SCHEMBL2961276 | 0.80 | MAP2K1 (0.58) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL6182186 | 0.80 | MAP2K1 (0.63) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL6991654 | 0.80 | MAP2K1 (0.87) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL6381926 | 0.79 | MAP2K1 (0.76) | MAP2K1EGFRERBB2SRC | |
| SCHEMBL5251276 | 0.79 | MAP2K1 (1.00) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL13915591 | 0.79 | MAP2K1 (0.75) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL2970612 | 0.78 | MAP2K1 (0.61) | MAP2K1RAF1EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767671-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2009-03-05 | — | — | US | disclosed |
| US-7449460-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2005082891-A1 | -QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | RAF1, KRAS, NRAS | MAP2K1 89/4885RAF1 1/4885EGFR 895/4885 |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | RAF1, KRAS, NRAS | MAP2K1 89/4885RAF1 1/4885EGFR 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.